CTKB (STOCKS)
Cytek Biosciences, Inc. Common Stock
$4.240000
+0.070000 (+1.68%)
Prev close: $4.170000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Medical Specialties
- CEO
- Wen Bin Jiang
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $544.70M
- Employees
- 688
- P/E (TTM)
- -41.94
- P/B (TTM)
- 1.43
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
4
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.04 | $-0.05 | +0.0136 | +25.37% |
|
Jun 2025 (Q2)
|
$-0.04 | $-0.07 | +0.0314 | +43.98% |
|
Mar 2025 (Q1)
|
$-0.09 | $-0.05 | -0.0441 | -96.08% |
|
Dec 2024 (Q4)
|
$0.07 | $0.05 | +0.0170 | +32.08% |
Financial Statements
| Revenues | $196.83M |
| Benefits Costs and Expenses | $212.32M |
| Cost Of Revenue | $91.60M |
| Costs And Expenses | $212.32M |
| Gross Profit | $105.23M |
| Nonoperating Income/Loss | $16.32M |
| Operating Expenses | $137.03M |
| Research and Development | $37.23M |
| Other Operating Expenses | $99.80M |
| Operating Income/Loss | -$31.81M |
| Income/Loss From Continuing Operations After Tax | -$12.82M |
| Income/Loss From Continuing Operations Before Tax | -$15.49M |
| Income Tax Expense/Benefit | -$2.67M |
| Income Tax Expense/Benefit, Deferred | -$7.91M |
| Net Income/Loss | -$12.82M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$12.82M |
| Net Income/Loss Available To Common Stockholders, Basic | -$12.82M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Average Shares | 382,311,663 |
| Diluted Average Shares | 382,311,663 |
| Assets | $494.92M |
| Current Assets | $388.49M |
| Inventory | $51.65M |
| Other Current Assets | $336.84M |
| Noncurrent Assets | $106.43M |
| Fixed Assets | $18.05M |
| Intangible Assets | $17.68M |
| Other Non-current Assets | $70.71M |
| Liabilities | $116.35M |
| Current Liabilities | $75.21M |
| Noncurrent Liabilities | $41.14M |
| Equity | $378.57M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $378.57M |
| Liabilities And Equity | $494.92M |
| Net Cash Flow From Operating Activities | -$1.92M |
| Net Cash Flow From Operating Activities, Continuing | -$1.92M |
| Net Cash Flow From Investing Activities | -$51.47M |
| Net Cash Flow From Investing Activities, Continuing | -$51.47M |
| Net Cash Flow From Financing Activities | -$15.85M |
| Net Cash Flow From Financing Activities, Continuing | -$15.85M |
| Exchange Gains/Losses | $215.00K |
| Net Cash Flow | -$69.02M |
| Net Cash Flow, Continuing | -$69.24M |
| Comprehensive Income/Loss | -$12.05M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$12.10M |
| Other Comprehensive Income/Loss | $773.00K |